C.R. Bard reentered the coronary balloon angioplasty market lastmonth after it received Food and Drug Administration approvalof its Probe III balloon catheter. Probe III is a fixed-wire balloon angioplasty catheter. Thistype of device makes up only 15%
C.R. Bard reentered the coronary balloon angioplasty market lastmonth after it received Food and Drug Administration approvalof its Probe III balloon catheter.
Probe III is a fixed-wire balloon angioplasty catheter. Thistype of device makes up only 15% of the total balloon cathetermarket, the rest being "over-the-wire" catheters. Bardhas several over-the-wire products awaiting FDA approval, thecompany said.
Bard's 45% position in the U.S. angioplasty catheter marketevaporated a year ago after it withdrew the Probe, Mini-Profile,Sprint and Solo catheters from the market. Most of Bard's problemsinvolved inadequate compliance with FDA regulations. There had,however, been complaints about defective performance of the Probedevice (SCAN 3/28/90).
Coronary angioplasty catheters are sold through Bard's USCIdivision in Billerica, MA. Although the bulk of the firm's angioplastysales are for cardiac applications, Bard also sells peripheralvascular balloon catheters to radiologists and other users. Thefirm continued to sell these angioplasty catheters, along withguidewires and other angioplasty accessories, while the coronarycatheter business was on hold, said William C. Bopp, Bard vicepresident and treasurer.
In fact, demand among radiologists for angioplasty and otherinterventional devices has been on the rise, he said. Bard formeda separate business unit, Bard Radiology, in November to targetthis user group (SCAN 12/26/90).
"Radiologists are performing more therapeutic and diagnostic(interventional procedures). That is why we formed Bard Radiology.This business center will initially sell products made by ourother divisions. But as they get to know the radiologist better,they will develop products specifically for that profession,"Bopp said.
Bard Radiology, based in Covington, GA, sells angioplasty andangiography catheters made by Bard Vascular, biopsy devices fromthe firm's urology division and drainage products from USCI, saidNancy Wolk, marketing manager for Bard Radiology.
BRIEFLY NOTED:
The two companies are among the world's four largest medicalimaging vendors. They have not indicated plans to cooperate inmedical systems, said Ted Kadoya, general manager of public communicationsfor Toshiba America in New York.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.